{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:11Z","timestamp":1786118891106,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1097\/bor.0b013e3282fb7caa","type":"journal-article","created":{"date-parts":[[2008,4,3]],"date-time":"2008-04-03T05:15:40Z","timestamp":1207199740000},"page":"251-256","source":"Crossref","is-referenced-by-count":26,"title":["Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis"],"prefix":"10.1097","volume":"20","author":[{"given":"Pradip","family":"Nandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle H","family":"Kingsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210128","doi-asserted-by":"crossref","first-page":"124","DOI":"10.7326\/0003-4819-148-2-200801150-00192","article-title":"Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis","volume":"148","author":"Donahue","year":"2008","journal-title":"Ann Intern Med"},{"key":"R2-5-20210128","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.22353","article-title":"Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis","volume":"55","author":"Finckh","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R3-5-20210128","first-page":"CD000959","article-title":"Antimalarials for treating rheumatoid arthritis.","volume":"4","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"R4-5-20210128","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1185\/030079907X219634","article-title":"Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial: an Indian experience","volume":"23","author":"Das","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"R5-5-20210128","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/ard.2006.069252","article-title":"QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries","volume":"66","author":"Sokka","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R6-5-20210128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1185\/030079906X80341","article-title":"Real-world utilization of dmards and biologics in rheumatoid arthritis: the radius (rheumatoid arthritis disease-modifying antirheumatic drug intervention and utilization study) study","volume":"22","author":"Gibofsky","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R7-5-20210128","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/rheumatology\/kel140","article-title":"Prevalence and management of rheumatoid arthritis in the general population of Greece: the ESORDIG study","volume":"45","author":"Andrianakos","year":"2006","journal-title":"Rheumatology"},{"key":"R8-5-20210128","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/MLR.0b013e318041384c","article-title":"Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (dmards) in patients with rheumatoid arthritis","volume":"45","author":"Grijalva","year":"2007","journal-title":"Med Care"},{"key":"R9-5-20210128","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1445-5994.2007.01396.x","article-title":"Has the use of disease-modifying antirheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the pharmaceutical benefits scheme?","volume":"37","author":"Lu","year":"2007","journal-title":"Intern Med J"},{"key":"R10-5-20210128","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/rheumatology\/kem143","article-title":"Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmo, Sweden","volume":"46","author":"Soderlin","year":"2007","journal-title":"Rheumatology"},{"key":"R11-5-20210128","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/art.22361","article-title":"Application of explicit process of care measurement to rheumatoid arthritis: moving from evidence to practice","volume":"55","author":"Kahn","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R12-5-20210128","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jbspin.2006.05.008","article-title":"Clinical practice format for choosing a second-line disease modifying antirheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line dmard therapy","volume":"74","author":"Meyer","year":"2007","journal-title":"Joint Bone Spine"},{"key":"R13-5-20210128","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/rheumatology\/kel144","article-title":"Are rheumatologists' treatment decisions influenced by patients' age?","volume":"45","author":"Fraenkel","year":"2006","journal-title":"Rheumatology"},{"key":"R14-5-20210128","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","article-title":"Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis","volume":"350","author":"Boers","year":"1997","journal-title":"Lancet"},{"key":"R17-5-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/ard.2006.057133","article-title":"Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study","volume":"66","author":"Capell","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R18-5-20210128","doi-asserted-by":"crossref","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","article-title":"Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial","volume":"146","author":"Goekoop-Ruiterman","year":"2007","journal-title":"Ann Intern Med"},{"key":"R19-5-20210128","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/art.21796","article-title":"Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study","volume":"54","author":"Hetland","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R20-5-20210128","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R21-5-20210128","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/ard.2006.066662","article-title":"Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score","volume":"66","author":"van der Kooij","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R22-5-20210128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.semarthrit.2007.02.001","article-title":"Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use","volume":"37","author":"Proudman","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"R23-5-20210128","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/rheumatology\/kem288","article-title":"Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis","volume":"47","author":"Verschueren","year":"2008","journal-title":"Rheumatology"},{"key":"R24-5-20210128","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard.2006.061820","article-title":"Step-up combination versus switching of nonbiological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study","volume":"66","author":"Schoels","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R26-5-20210128","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/art.22467","article-title":"A randomized controlled trial of early intervention with intraarticular corticosteroids followed by sulfasalazine versus conservative treatment in early oligoarthritis","volume":"57","author":"Marzo-Ortega","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R27-5-20210128","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/kem076","article-title":"Antirheumatic drug use and risk of serious infections in rheumatoid arthritis","volume":"46","author":"Bernatsky","year":"2007","journal-title":"Rheumatology"},{"key":"R28-5-20210128","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/art.23003","article-title":"The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis","volume":"57","author":"Edwards","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R29-5-20210128","first-page":"2201","article-title":"Leflunomide-associated infections in rheumatoid arthritis","volume":"34","author":"Jenks","year":"2007","journal-title":"J Rheumatol"},{"key":"R30-5-20210128","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0140-6736(04)15969-2","article-title":"Interstitial lung disease and disease modifying antirheumatic drugs","volume":"363","author":"Scott","year":"2004","journal-title":"Lancet"},{"key":"R31-5-20210128","first-page":"1934","article-title":"Hypersensitivity pneumonitis associated with leflunomide therapy","volume":"34","author":"Martin","year":"2007","journal-title":"J Rheumatol"},{"key":"R32-5-20210128","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.21806","article-title":"Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis","volume":"54","author":"Suissa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R33-5-20210128","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/art.22666","article-title":"Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis","volume":"56","author":"Ju","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R34-5-20210128","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1186\/ar2045","article-title":"Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study","volume":"8","author":"van Halm","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R35-5-20210128","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1002\/art.22255","article-title":"Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis","volume":"54","author":"Solomon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R36-5-20210128","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jama.298.2.187","article-title":"Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis","volume":"298","author":"Wasko","year":"2007","journal-title":"JAMA"},{"key":"R37-5-20210128","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/ard.2006.068296","article-title":"Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial)","volume":"66","author":"Goekoop-Ruiterman","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R38-5-20210128","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/ard.2006.067447","article-title":"Why are Dutch rheumatologists reluctant to use the cobra treatment strategy in early rheumatoid arthritis?","volume":"66","author":"van Tuyl","year":"2007","journal-title":"Ann Rheum Dis"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0b013e3282fb7caa","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:59:05Z","timestamp":1786035545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-200805000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e3282fb7caa","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}